Authorized purpose: Adjunctive alert and second-reader information for radiologists interpreting non-contrast chest CT in asymptomatic populations; the cleared nodule range is 3-20 mm.
Clinical role
Adjunctive alert and second reader after the radiologist's first read.
Images and patients
CT/CTA · Chest/Lung
Key limitation
Keep in mind: The software is an adjunct, not a replacement for radiologist interpretation. The cleared population is asymptomatic, the input is non-contrast chest CT, and the FDA summary recommends limiting use to Siemens SOMATOM series.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Adjunctive alert and second-reader information for radiologists interpreting non-contrast chest CT in asymptomatic populations; the cleared nodule range is 3-20 mm.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest/Lung Input: Non-contrast chest CT for asymptomatic populations; FDA recommends limiting use to Siemens SOMATOM series because the validation data were predominantly from that scanner family.
Who uses it?Intended users: Radiologists and other qualified healthcare professionals interpreting chest CT.
What does the software produce?Output: Detected pulmonary nodules with marked regions of interest and quantified nodule values for radiologist review.
What is its most important limitation?Key limitation: The software is an adjunct, not a replacement for radiologist interpretation. The cleared population is asymptomatic, the input is non-contrast chest CT, and the FDA summary recommends limiting use to Siemens SOMATOM series.
Clinical takeaway. Clinical role: Adjunctive alert and second-reader information for radiologists interpreting non-contrast chest CT in asymptomatic populations; the cleared nodule range is 3-20 mm.
Evidence takeaway. Evidence from the reviewed source record: The FDA summary describes nonclinical/software validation for nodule detection and analysis and states that no clinical study was considered necessary for this submission.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Adjunctive alert and second-reader information for radiologists interpreting non-contrast chest CT in asymptomatic populations; the cleared nodule range is 3-20 mm.
Non-contrast chest CT for asymptomatic populations; FDA recommends limiting use to Siemens SOMATOM series because the validation data were predominantly from that scanner family.
The software is an adjunct, not a replacement for radiologist interpretation. The cleared population is asymptomatic, the input is non-contrast chest CT, and the FDA summary recommends limiting use to Siemens SOMATOM series.
The FDA summary describes nonclinical/software validation for nodule detection and analysis and states that no clinical study was considered necessary for this submission.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The FDA summary describes nonclinical/software validation for nodule detection and analysis and states that no clinical study was considered necessary for this submission.
No single exact-submission clinical sensitivity endpoint was established in the reviewed FDA summary.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-07
No single exact-submission clinical specificity endpoint was established in the reviewed FDA summary.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
AVIEW Lung Nodule CAD K251203 validation
DesignNonclinical and software validation described in the FDA 510(k) summary
PopulationNon-contrast chest CT studies with pulmonary nodules in the cleared 3-20 mm range, predominantly acquired on Siemens SOMATOM scanners
Scopeexact submission
Tested versionAVIEW Lung Nodule CAD 2.0
IndependenceSponsor or vendor study
K251203
The public summary does not establish a clinical-outcome study or one consolidated sensitivity/specificity result.
Medicare National Coverage Determination 210.14 (version effective 2022-02-10) covers annual lung cancer screening with low dose CT under Part B as a preventive service for eligible beneficiaries (age 50-77, asymptomatic, at least 20 pack-years, current smoker or quit within 15 years, with an order and a prior counseling and shared decision-making visit). It requires a board-certified or board-eligible reading radiologist and a facility that uses a standardized lung nodule identification, classification and reporting system. The NCD does not mention AI or nodule-detection software. This is national service-level context, not a determination that this exact product is covered or separately paid. No payment amount or software-specific code was reviewed.
National coverage of the LDCT lung screening service (NCD 210.14); software-specific coverage and payment not established
Medicare (Original Medicare, CMS) · United States · Effective 2022-02-10
The NCD covers the screening service and does not address AI software. It does not prove eligibility, coverage or separate payment for this product, version, patient, site or claim.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Non-contrast chest CT for asymptomatic populations; FDA recommends limiting use to Siemens SOMATOM series because the validation data were predominantly from that scanner family.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Processes the CT study and presents nodule findings as radiologist-review information in the imaging workflow; exact local routing and PACS configuration require site confirmation.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Standalone software configuration described in the submission; the exact hosting and local service topology are not specified in the public summary.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Detected pulmonary nodules with marked regions of interest and quantified nodule values for radiologist review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Processes the CT study and presents nodule findings as radiologist-review information in the imaging workflow; exact local routing and PACS configuration require site confirmation.
Coreline Soft states that AVIEW Lung Nodule CAD received US FDA 510(k) clearance renewal after meeting the FDA's strengthened cybersecurity review criteria, including security lifecycle management, Software Bill of Materials (SBOM) submission, encryption and access control, and vulnerability response systems.
Product family
Checked 2026-10-26
Vendor statement, not an attestation. Scope is the AVIEW Lung Nodule CAD product family as named in Coreline Soft's own news release; not extended to other AVIEW products.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-07Last searched
20Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
Stored candidate metadata was screened; no PubMed or trial IDs were returned for this submission. This is not a full-paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, stored candidate metadata, literature index, trial registry, payer policy, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission
No public price or quote for the K251203 configuration was reviewed.
Pricing model: Not verified - checked 2026-09-07 - Exact FDA submission
License, per-study, subscription and implementation terms were not established.
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.
Authorized purpose: Quantitative support for thoracic CT interpretation and treatment planning, including emphysema burden, airway/lung segmentation, endobronchial valve assessment and estimated chronic perfusion defect.
Authorized purpose: Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.
Authorized purpose: V5med Lung AI provides concurrent-read adjunctive notification of suspected pulmonary nodules on chest CT; it does not replace radiologist judgment, diagnostic processes, or review of original CT series.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.